About: Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies
Creator	Joshi, S Armitage, J Bierman, P Bishop, M Gross, T Kessinger, A Kollath, J Nasrati, K Pavletic, Z Pirruccello, S Reed, E Tarantolo, S Vose, J Warkentin, P
Source	PMC
abstract	Forty-one patients were studied at set times after allogeneic blood stem cell transplantation (alloBSCT) for recovery of lymphocyte numbers and function. Cells were mobilized with G-CSF from HLA-matched related donors and cryopreserved. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate; G-CSF was administered post-transplant. Median time to absolute lymphocyte count (ALC) ⩾500/μl was 17 days vs 41 and 49 days in historical alloBMT patients with G-CSF (n = 23) or no cytokine (n = 29) post-transplant, respectively (P < 0.0001). CD4/CD8(+) ratio was 1.9 on day 28 after alloBSCT, then gradually declined to 0.8 at 1 year due to more rapid CD8(+) cell recovery. Mean phytohemagglutinin-induced T cell responses were lower than normal on day +28 (P < 0.05), then tended to recover towards normal values. Natural-killer cytotoxicity remained low from day +28 to 1 year post-alloBSCT, but considerable lymphokine-activated killer cytotoxicity was induced from cells already obtained on day +28. Faster lymphocyte recovery correlated with better survival in alloBSCT patients (median follow-up 287 days, P = 0.002), ALC recovery was not affected by acute GVHD, CMV infections or doses of infused cells. ALC recovery did not correlate with survival in either historical alloBMT group. These data suggest that after alloBSCT lymphocyte reconstitution is faster than after alloBMT, and that quicker lymphocyte recovery predicts better survival in the alloBSCT setting.
has issue date	1998-02-13(xsd:dateTime)
bibo:doi	10.1038/sj.bmt.1701037
bibo:pmid	9486492
has license	no-cc
sha1sum (hex)	057922c1f1c71eb9695aa65f15e6d0a3577d6cbe
schema:url	https://doi.org/10.1038/sj.bmt.1701037
resource representing a document's title	Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies
has PubMed Central identifier	PMC7101861
has PubMed identifier	9486492
schema:publication	Bone Marrow Transplant
resource representing a document's body	covid:057922c1f1c71eb9695aa65f15e6d0a3577d6cbe#body_text
is schema:about of	named entity 'group' named entity 'T cell' named entity '17 days' named entity 'infused' named entity 'G-CSF' named entity 'MEDIAN' named entity 'T CELL' named entity '0.05' named entity 'CD4' named entity 'ABSOLUTE LYMPHOCYTE COUNT' named entity 'RECONSTITUTION' named entity 'METHOTREXATE' named entity 'CRYOPRESERVED' named entity 'NATURAL' named entity 'ALLOGENEIC' named entity 'ALC' named entity 'MEAN' named entity 'THESE' named entity '28P' named entity 'DATA' named entity 'DUE TO' named entity 'GRAFT-VERSUS-HOST DISEASE' named entity 'numbers' named entity 'GVHD' named entity 'responses' named entity 'correlated' named entity 'patients' named entity 'cells' named entity 'Median' named entity 'recovery' named entity 'patients' named entity 'cytotoxicity' named entity 'set' named entity 'reconstitution' named entity 'cytokine' named entity 'cytotoxicity' named entity 'ALC' named entity 'cyclosporine' named entity 'hematologic malignancies' named entity 'prophylaxis' named entity 'lysed' named entity 'monocytes' named entity 'colony-forming unit' named entity 'GVHD' named entity 'follow-up' named entity 'centrifuged' named entity 'cytotoxicity' named entity 'lymphoma' named entity 'Amersham' named entity 'CD4' named entity 'blood stem cell' named entity 'monocyte' named entity 'subcutaneous administration' named entity 'Apheresis' named entity 'CD8' named entity 'thymidine' named entity 'Irvine, CA' named entity 'pneumonia' named entity 'CD3' named entity 'IL-2' named entity 'cytotoxicity' named entity 'correlation' named entity 'cytomegalovirus' named entity 'CD3' named entity 'phase II trial' named entity 'G-CSF' named entity 'G-CSF' named entity 'ALC'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software